Investor Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Shareholder Letter - August 2018

Press Releases

Date Title and Summary
Toggle Summary Rexahn Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans
ROCKVILLE, Md. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced that it has distributed to shareholders a mid-year update letter
Toggle Summary Rexahn Reports Second Quarter 2018 Financial Results
ROCKVILLE, Md. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced financial results for the second quarter ended June 30, 2018 .
Toggle Summary Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018
Three of four proposals pass with shareholder approval Annual Meeting adjourned solely with respect to Proposal 3 — approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock ROCKVILLE, Md., June 14, 2018

Events & Presentations

Date Event Details
Summary Toggle Jun 1-5, 2018 Jun 1, 2018 06/01/18

Title:   Preliminary Results From an Ongoing Phase 2a Study of RX, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC)  [View Poster]

Title:  Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68),  Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC)    [View Poster]

Summary Toggle Apr 14-18, 2018 Apr 14, 2018 04/14/18

Title: RX-3117 promotes epigenetic effects in cancer cells through enhanced degradation of DNMT1 [View Poster]

Location

Chicago, Illinois
Summary Toggle Jan 9, 2018
12:00 AM PST
Jan 9, 2018 12:00 AM PST 01/09/18


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy